691857-46-2

Basic information

• Product Name: 3-Benzofurancarboxylic acid, 2-(4-fluorophenyl)-5-hydroxy-6-nitro-, ethyl ester
• Synonyms: 3-Benzofurancarboxylic acid, 2-(4-fluorophenyl)-5-hydroxy-6-nitro-, ethyl ester;ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate
• CAS NO: 691857-46-2
• Molecular Formula: C₁₇H₁₂FNO₆
• Molecular Weight: 345.2786832
• Mol File: 691857-46-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Benzofurancarboxylic acid, 2-(4-fluorophenyl)-5-hydroxy-6-nitro-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzofurancarboxylic acid, 2-(4-fluorophenyl)-5-hydroxy-6-nitro-, ethyl ester(691857-46-2)
• EPA Substance Registry System: 3-Benzofurancarboxylic acid, 2-(4-fluorophenyl)-5-hydroxy-6-nitro-, ethyl ester(691857-46-2)

Safety Data

• Hazardous Substances Data: 691857-46-2(Hazardous Substances Data)

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 691856-86-7 ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate 
• 691857-07-5 ethyl 2-(4-fluorophenyl)-5-isopropoxy-6-nitrobenzofuran-3-carboxylate 
• 691856-87-8 ethyl 2-(4-fluorophenyl)-5-isopropoxybenzofuran-3-carboxylate 
• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 691857-51-9 ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate 
• 1217340-48-1 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylic acid 

Relevant articles and documents

Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold

This letter describes the discovery of a fused benzofuran scaffold viable for preparing a series of novel potent HCV NS5B polymerase non-nucleoside inhibitors. Designed on the basis of the functionalized benzofuran derivative nesbuvir (HCV-796), these com

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

HEPATITIS C INHIBITORS AND USES THEREOF

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

INHIBITORS OF HEPATITIS C VIRUS

A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN

Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of 5-cyclopropyl-2- (4-fluoro-phenyl-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran- 3-carboxylic acid methylamide or a pharmaceutically acceptable salt thereof with natural, recombinant or modified interferon, that effectively inhibit viral replication.